Metabolic dysfunction associated steatotic liver disease (MASALD): From research to clinic

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects up to 65% of people living with type 2 diabetes, which is more than double compared to the general population.  There is growing recognition that type 2 diabetes is a significant risk factor in the pathogenesis of MASLD.  This session, which is relevant to everyone within the multi-disciplinary diabetes team, highlights why MASLD matters in people living with type 2 diabetes and how to screen for MASLD in the general population. The patients’ perspective of living with type 2 diabetes and MASLD and future therapies for the condition will also be discussed.